The German-based medical device company, Coramaze Technologies, has developed the mitramaze valve repair system, which is a catheter-based valve that can be implanted directly into the beating heart. The system targets inoperable and asymptomatic patients suffering from functional mitral regurgitation (fMR), which is caused by enlargement of the heart due to heart attack or heart failure. The company's Tripair device repairs functional Tricuspid Regurgitation (fTR) in heart failure patients, improving their quality of life and reducing morbidity. The Tripair implant is anchored a-traumatically in the right atrium, allowing for full retrievability and intra-procedural efficacy evaluation. Coramaze Technologies' innovative valve repair systems provide less invasive procedures for heart patients who would otherwise be inoperable.